New Truvada Lawsuits: Taking on Gilead Sciences for Kidney and Bone Injuries

Los Angeles, CA – Our law firm is now accepting Truvada lawsuits and other HIV drug injury lawsuits across all 50 states. We believe that HIV drugs containing tenofovir disoproxil fumarate (TDF) pose a risk to patients, leading to lawsuits alleging kidney disease, bone density loss, bone injuries, and other side effects.

Two of the first brand-name drugs developed by Gilead Sciences to treat HIV, Viread and Truvada, are at the center of these lawsuits. These drugs utilize tenofovir disoproxil fumarate (TDF), a new type of antiviral drug that was initially praised for its effectiveness in slowing HIV.

However, it became apparent that TDF drugs like Viread and Truvada had serious health consequences for some patients. These drugs are highly toxic to the kidneys and bones, often resulting in permanent kidney failure and bone fractures.

As a result, patients who used Viread and Truvada are filing product liability lawsuits against Gilead, seeking financial compensation for their kidney and bone injuries. If you have taken a Gilead HIV drug and experienced kidney damage or bone problems, you may be entitled to compensation. Contact our law firm today for a free online consultation.

In the latest Truvada lawsuit update, rulings are still pending in the Truvada HIV lawsuits in California. The court has ordered supplemental briefing to determine the legal standards for determining when a prescription drug is considered “defective.” The court is also seeking clarification on whether a safer alternative design must work equally well for all patients or solely for the plaintiffs.

In November 2023, Gilead’s attempt to dismiss the HIV drug lawsuits was rejected by a federal court in California. The judge ruled that Gilead cannot avoid design defect and warning-related claims, suggesting that the company prioritized profits over the development of safer HIV drugs.

In September 2023, the first major Truvada lawsuit trial is set to begin in California on January 24, 2024. This bellwether trial will have significant implications for future Truvada settlement amounts.

Gilead is also facing claims from over 24,000 patients who allege that the company deliberately delayed the release of a new, safer HIV drug to maximize profits. Gilead argues that there is no legal duty for a pharmaceutical company to release safer drugs promptly.

In August 2023, there was a significant increase in the volume of calls and inquiries about Truvada and Viread lawsuits following a New York Times article that substantiated the claims made in the lawsuits.

Despite ongoing litigation, Gilead won a major antitrust trial last month, where a jury ruled that the company did not pay to delay the entry of competing HIV drugs into the market.

Since 2018, numerous product liability lawsuits have been filed against Gilead by users of TDF drugs like Truvada and Viread. These lawsuits allege that Gilead manufactured drugs that were unreasonably toxic to patients’ kidneys and bones and failed to provide adequate warnings about the risks.

Gilead is accused of withholding a safer alternative drug, TAF, which was more effective and less toxic than TDF. The company allegedly delayed the release of TAF to maximize profits from TDF sales.

In conclusion, Truvada lawsuits continue to be filed nationwide, alleging that Gilead prioritized profits over patient safety. These lawsuits seek compensation for kidney damage, bone fractures, and other serious health consequences caused by TDF drugs. Rulings are pending in California, and a bellwether trial is set for early 2024.